Skip to main content
Top
Published in: PharmacoEconomics 5/2000

01-05-2000 | Consensus Conference Papers

Assessing Quality in Decision Analytic Cost-Effectiveness Models

A Suggested Framework and Example of Application

Authors: Dr Mark Sculpher, Elisabeth Fenwick, Karl Claxton

Published in: PharmacoEconomics | Issue 5/2000

Login to get access

Abstract

Despite the growing use of decision analytic modelling in cost-effectiveness analysis, there is a relatively small literature on what constitutes good practice in decision analysis. The aim of this paper is to consider the concept of ‘validity’ and ‘quality’ in this area of evaluation, and to suggest a framework by which quality can be demonstrated on the part of the analyst and assessed by the reviewer and user.
The paper begins by considering the purpose of cost-effectiveness models and argues that the their role is to identify optimum treatment decisions in the context of uncertainty about future states of the world. The issue of whether such models can be defined as ‘scientific’ is considered. The notion that decision analysis undertaken at time t can only be considered scientific if its outputs closely predict the results of a trial undertaken at time t+1 is rejected as this ignores the need to make decisions on the basis of currently available evidence. Rather, the scientific characteristic of decision models is based on the fact that, in principle at least, such analyses can be falsified by comparison of two states of the world, one where resource allocation decisions are based on formal decision analysis and the other where such decisions are not. This section of the paper also rejects the idea of exact codification of scientific method in general, and of decision analysis in particular, as this risks rejecting potentially valuable models, may discourage the development of novel methods and can distort research priorities. However, the paper argues that it is both possible and necessary to develop a framework for assessing quality in decision models.
Building on earlier work, various dimensions of quality in decision modelling are considered: model structure (disease states, options, time horizon and cycle length); data (identification, incorporation, handling uncertainty); and consistency (internal and external). Within this taxonomy a (nonexhaustive) list of questions about quality is suggested which are illustrated by their application to a specific published model. The paper argues that such a framework can never be prescriptive about every aspect of decision modelling. Rather, it should encourage the analyst to provide an explicit and comprehensive justification of their methods, and allow the user of the model to make an informed judgment about the relevance, coherence and usefulness of the analysis.
Literature
1.
go back to reference Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322–38PubMedCrossRef Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322–38PubMedCrossRef
2.
go back to reference Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185–205CrossRef Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185–205CrossRef
3.
go back to reference Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996
4.
go back to reference Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409PubMedCrossRef Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409PubMedCrossRef
5.
go back to reference Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11PubMedCrossRef Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11PubMedCrossRef
6.
go back to reference Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27PubMedCrossRef Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27PubMedCrossRef
7.
go back to reference Popper KR. The logic of scientific discovery. London: Hitchinson, 1972 Popper KR. The logic of scientific discovery. London: Hitchinson, 1972
8.
go back to reference Lakatos I. Falsification and the methodology of scientific research programmes. In: Lakatos I, Musgrave, A, editors. Criticism and the growth of knowledge. Cambridge: Cambridge University Press, 1970: 91–195 Lakatos I. Falsification and the methodology of scientific research programmes. In: Lakatos I, Musgrave, A, editors. Criticism and the growth of knowledge. Cambridge: Cambridge University Press, 1970: 91–195
9.
go back to reference Manning R, Claxton K. Experimental and econometric solutions to selection bias. The International Health Economics Association Meeting, 1999 Jun 6–9; Rotterdam Manning R, Claxton K. Experimental and econometric solutions to selection bias. The International Health Economics Association Meeting, 1999 Jun 6–9; Rotterdam
10.
go back to reference Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637–48PubMedCrossRef Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637–48PubMedCrossRef
11.
go back to reference Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 Suppl.: JS52–64 Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 Suppl.: JS52–64
12.
go back to reference Russell B. My philosophical development. London: Routledge, 1959 Russell B. My philosophical development. London: Routledge, 1959
13.
go back to reference Sokal A, Bricmont J. Intellectual impostures. London: Profile Books, 1998 Sokal A, Bricmont J. Intellectual impostures. London: Profile Books, 1998
14.
go back to reference Feyerabend P. Against method. London: New Left Books, 1975 Feyerabend P. Against method. London: New Left Books, 1975
15.
go back to reference Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996; 276: 637–9PubMedCrossRef Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996; 276: 637–9PubMedCrossRef
16.
go back to reference Guyatt GH, Sackett DL, Cook DJ. Users’ guides to the medical literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59–63PubMedCrossRef Guyatt GH, Sackett DL, Cook DJ. Users’ guides to the medical literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59–63PubMedCrossRef
18.
go back to reference Eddy DM. Technology assessment: the role of mathematical modeling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–53 Eddy DM. Technology assessment: the role of mathematical modeling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–53
19.
go back to reference Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131–47PubMedCrossRef Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131–47PubMedCrossRef
20.
go back to reference Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press, 1997 Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press, 1997
21.
go back to reference Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef
22.
23.
go back to reference Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42PubMedCrossRef Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42PubMedCrossRef
24.
go back to reference Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345–55PubMed Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345–55PubMed
25.
go back to reference Mohr P, Neumann P, Claxton K. Letter to the editor. Am J Manag Care 1998; 4: 1200–1 Mohr P, Neumann P, Claxton K. Letter to the editor. Am J Manag Care 1998; 4: 1200–1
26.
go back to reference Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994; 36: 726–36PubMedCrossRef Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994; 36: 726–36PubMedCrossRef
27.
go back to reference Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522–3 Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522–3
28.
go back to reference Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993 Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993
29.
go back to reference Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; 33: 911–28PubMed Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; 33: 911–28PubMed
30.
go back to reference Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897–906PubMedCrossRef Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897–906PubMedCrossRef
31.
go back to reference Van Doorslaer EKA. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis. Dermatology 1996; 193: 239–44PubMedCrossRef Van Doorslaer EKA. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis. Dermatology 1996; 193: 239–44PubMedCrossRef
32.
go back to reference Sculpher M, Michaels J, McKenna M, et al. Acost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104–25PubMedCrossRef Sculpher M, Michaels J, McKenna M, et al. Acost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104–25PubMedCrossRef
33.
go back to reference Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247–57PubMedCrossRef Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247–57PubMedCrossRef
34.
go back to reference Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789–96PubMedCrossRef Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789–96PubMedCrossRef
35.
go back to reference Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64–76PubMed Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64–76PubMed
36.
go back to reference Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–8PubMedCrossRef Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–8PubMedCrossRef
37.
go back to reference Dowie J. Evidence-based, cost-effective and preference-driven medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1996; 1: 104–13PubMed Dowie J. Evidence-based, cost-effective and preference-driven medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1996; 1: 104–13PubMed
38.
go back to reference Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. Centre for Health Economics (CHE) discussion paper. York: CHE, University of York. In press Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. Centre for Health Economics (CHE) discussion paper. York: CHE, University of York. In press
39.
go back to reference Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104PubMedCrossRef Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104PubMedCrossRef
40.
go back to reference Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996; 24: 1008–34CrossRef Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996; 24: 1008–34CrossRef
41.
go back to reference Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992; 12: 53–63PubMedCrossRef Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992; 12: 53–63PubMedCrossRef
42.
go back to reference Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means. Med Decis Making 1997; 17: 483–9PubMedCrossRef Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means. Med Decis Making 1997; 17: 483–9PubMedCrossRef
43.
go back to reference Tosteson ANA, Rosenthal DI, Melton J, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed Tosteson ANA, Rosenthal DI, Melton J, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed
44.
go back to reference Briggs A, Sculpher M, Britton A, et al. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assess Health Care 1998; 14 (4): 743–61PubMedCrossRef Briggs A, Sculpher M, Britton A, et al. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assess Health Care 1998; 14 (4): 743–61PubMedCrossRef
Metadata
Title
Assessing Quality in Decision Analytic Cost-Effectiveness Models
A Suggested Framework and Example of Application
Authors
Dr Mark Sculpher
Elisabeth Fenwick
Karl Claxton
Publication date
01-05-2000
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 5/2000
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200017050-00005

Other articles of this Issue 5/2000

PharmacoEconomics 5/2000 Go to the issue

Consensus Conference Papers

Modelling in Health Economic Evaluation